No human study has shown that platelet-rich plasma injections cause cancer to spread, but the theoretical concern is real enough that expert panels list active cancer as a contraindication. PRP is a concentrate of your own platelets and the growth factors they carry, and several of those growth factors are the same ones tumors hijack to build blood vessels and grow. The gap between “theoretically risky” and “proven dangerous” is where most of the science currently sits, and the answer you get depends heavily on whether you are talking about a person with active disease or someone years into remission.
Why the Concern Exists in the First Place
Platelets do far more than stop bleeding. When activated, they release a cocktail of signaling molecules, including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and transforming growth factor beta (TGF-β). These molecules are exactly what makes PRP useful for healing tendons and surgical wounds: they recruit stem cells, stimulate new blood vessel formation, and accelerate tissue repair. The problem is that tumors rely on nearly identical processes to sustain themselves. A growing tumor needs new blood vessels to feed it, and it needs growth signals to keep dividing. In principle, flooding an area with platelet-derived growth factors could give a dormant or residual tumor cell exactly the push it needs.
A 2020 review in Heliyon laid out this concern plainly: because PRP contains both angiogenesis inhibitors and stimulators, its net effect on tumor biology is not straightforward, and administering PRP at a site previously affected by a malignant tumor could theoretically trigger proliferation from residual cancer cells.1Heliyon. Can PRP Spread Cancer? A Look at the Science – Section: 2 The role played by PRP in cancer treatment That same review noted that PRP stimulates endothelial cells near the application site, favoring new blood vessel formation, a process central to how tumors grow beyond a tiny size.
What Happens in the Lab
When researchers expose cancer cells to PRP or platelet-derived substances in a dish, the results depend heavily on the type of cancer cell and the specific experiment. One study found that platelet releasate significantly increased the proliferation of both MCF-7 and MDA-MB-231 breast cancer cell lines, with cells growing faster and more aggressively when exposed to platelet-derived factors.2British Journal of Cancer. Platelet releasate promotes breast cancer growth and angiogenesis via VEGF–integrin cooperative signalling Another lab study using PRP as a source of growth factors and a fibrin scaffold found that certain breast cancer subtypes, specifically luminal B and HER2-positive cells, showed robust new blood vessel formation when co-cultured with endothelial cells in the presence of PRP.3PubMed Central. Interface between breast cancer cells and the tumor microenvironment using platelet-rich plasma to promote tumor angiogenesis – influence of platelets and fibrin bundles on the behavior of breast tumor cells
Yet a 2024 study found the opposite for the same aggressive breast cancer cell line: PRP inhibited the proliferation, migration, and invasion of MDA-MB-231 cells in the lab.4PubMed Central. Platelet-Rich Plasma Inhibits Breast Cancer Proliferation That is the same cell line another group found was stimulated by platelet factors. The contradiction is not necessarily a sign that someone made an error. PRP is not a single standardized product. Differences in how it is prepared, how it is activated, and how concentrated it is can produce very different biological effects, and that variability is one of the biggest challenges in interpreting the research.
Animal Studies Add More Uncertainty
A fibrosarcoma study in mice provides one of the more interesting data points. Researchers removed tumors surgically and then applied PRP gel to the surgical site. Mice treated with PRP had smaller tumor volumes when cancer did recur (about 300 cubic millimeters versus roughly 1,000 in untreated controls), and recurrence appeared later in the PRP group. None of the PRP-treated mice reached the tumor-size cutoff that required euthanasia within the study period, while one control mouse did. The results were not statistically significant because of the small number of animals, but they pointed toward PRP slowing rather than accelerating local recurrence after surgery.5Springer Medizin. The effects of the use of platelet-rich plasma gel on local recurrence in an animal model of human fibrosarcoma
On the other hand, a rat model of chemically induced skin cancer told a less reassuring story. Rats that received PRP along with skin grafts after tumor removal showed a statistically significant increase in tumor recurrence with nodulation at the 20-week mark compared to rats that did not receive PRP.6Acta Cirúrgica Brasileira. Skin graft associated with platelet-rich plasma in correcting extensive injuries resulting from the resection of skin cancer chemically induced in rats That difference disappeared at other time points, but the finding is hard to dismiss entirely. These two animal studies illustrate the fundamental ambiguity in the field: depending on the cancer type, the model, and the timing, PRP can appear either protective or harmful.
Clinical Evidence in Cancer Patients
The human data, while limited, is more reassuring than the lab work might suggest. A study of 163 breast cancer patients who underwent sentinel lymph node biopsy found that those treated with PRP had no distant metastases, no local recurrences, and 100% overall survival at 30 months. The complication rate was actually lower in the PRP group (zero revisions) compared to controls (about one percent requiring revision), though neither difference reached statistical significance.7PubMed Central. Platelet-Rich Plasma (PRP) in Breast Cancer Patients: An Application Analysis of 163 Sentinel Lymph Node Biopsies
A separate study tracked 89 breast cancer patients who had PRP applied to subcutaneous port scars after chemotherapy. Over a follow-up averaging around six years, there was no cancer recurrence within the treated scar area. The estimated local recurrence-free survival was virtually identical between the PRP group and controls (roughly 73 months in both groups), with no statistically significant difference. The same held for distant recurrence-free survival. No deaths occurred in the PRP group during the study period, compared to four in the control group, though the researchers attributed that numerical advantage to coincidence rather than any protective effect of PRP.8PubMed Central. Platelet-rich plasma (PRP) in oncological patients: long-term oncological outcome analysis of the treatment of subcutaneous venous access device scars in 89 breast cancer patients
These are encouraging numbers, but they come with caveats. Both studies involved breast cancer patients whose primary tumors had been removed and who were receiving standard oncological treatment. They are not evidence that PRP is safe to use in someone with active, untreated cancer or at a site where tumor cells are still present. What they do suggest is that in the post-surgical, post-treatment setting, PRP applied to a wound site does not appear to trigger recurrence over several years of follow-up.
Platelets Already Play a Role in Metastasis
Part of the anxiety around PRP and cancer comes from what we already know about platelets in the body’s own tumor biology. Circulating platelets are not innocent bystanders when cancer cells enter the bloodstream. They actively coat circulating tumor cells, shielding them from immune detection and helping them stick to blood vessel walls. A computational and experimental study found that increasing the number of platelets attached to a circulating tumor cell caused that cell to adhere to the vessel wall faster, with the firm adhesion happening roughly 40% sooner when 15 platelets were attached compared to five.9Scientific Reports. Interactions of platelets with circulating tumor cells contribute to cancer metastasis
Platelets also help create a welcoming environment at distant sites. A 2023 review described how platelets mediate tumor cell arrest, extravasation, and angiogenesis in distant organs, essentially helping to build a metastatic niche.10PubMed Central. The critical role of platelet in cancer progression and metastasis Another comprehensive review detailed how platelets promote tumor invasion and metastasis through immune escape, angiogenesis, and tumor cell homing.11PubMed Central. The role of platelets in the regulation of tumor growth and metastasis: the mechanisms and targeted therapy
This is important context for the PRP question, but it also matters to understand the distinction. These findings describe what normal circulating platelets do when they encounter tumor cells in the bloodstream. A PRP injection is a local deposit of concentrated platelets at a specific site, not a systemic increase in circulating platelet count. The mechanisms are related but not identical, and the clinical implications may be quite different.
PRP Does Have Systemic Effects
That said, PRP injections are not purely local events. A study measuring blood levels of growth factors after PRP injection found that VEGF, a potent promoter of blood vessel growth, was elevated in all 25 patients at multiple time points up to 96 hours after treatment. IGF-1 levels rose at 24 and 48 hours, and basic fibroblast growth factor (bFGF) increased at 72 and 96 hours.12PubMed. The systemic effects of platelet-rich plasma injection These are not trivial molecules from an oncology standpoint. VEGF in particular is the target of multiple cancer drugs designed specifically to block new blood vessel formation around tumors.
Whether these transient systemic elevations are enough to meaningfully affect a tumor somewhere else in the body is unknown. The increases are temporary, peaking over a few days and then returning to baseline. For comparison, your body produces spikes in many of these same growth factors during normal wound healing, exercise, and inflammation. Still, the finding undercuts the common reassurance that PRP “stays local.” It mostly does, but its chemical signals leak into the bloodstream for several days.
What Expert Panels Actually Recommend
A 2025 formal consensus from an international research group on platelet injections addressed the oncology question directly. The panel concluded that PRP injections should not be performed near local benign or malignant tumors, because of the risk that released growth factors could promote tumor growth. Active cancer, whether localized or metastatic, was listed as a contraindication, partly because of the growth factor concern and partly because of a theoretical risk of carrying metastatic cells to the injection site through the blood draw and re-injection process.13PubMed Central. Indications and contraindications to platelet‐rich plasma injections in musculoskeletal diseases in case of infectious, oncological and haematological comorbidities: A 2025 formal consensus from the GRIIP (International Research Group on Platelet Injections)
The same panel made an important distinction for cancer survivors. A cured or in-remission cancer that was originally localized does not constitute a contraindication to PRP injections. If the cancer was originally metastatic, PRP can still be used but requires the agreement of the treating oncologist. This tiered approach reflects the real-world clinical picture: the concern is primarily about fueling active disease or disturbing a site where residual tumor cells might linger, not about triggering entirely new cancers in someone who has been cancer-free for years.
How PRP Preparation Changes the Equation
One reason the lab results are so inconsistent is that “PRP” is not a single product. The way platelets are concentrated, what is used to activate them, and whether white blood cells are included all change what comes out of the syringe. A study comparing different activation methods found that the choice of activator affects both the amount and the timing of growth factor release. Calcium chloride produced a slow, progressive release of growth factors building over 24 hours, while thrombin and collagen-type-I activation caused an immediate burst of PDGF and TGF-β1 that then plateaued, with VEGF continuing to climb over a full day regardless of the method.14PubMed Central. Platelet-Rich Plasma: The Choice of Activation Method Affects the Release of Bioactive Molecules
The leukocyte content of PRP is another variable that matters. Leukocyte-rich PRP contains white blood cells that release their own set of inflammatory and immune-modulating signals. These can have both positive effects, like antimicrobial activity and immune modulation, and negative effects, like releasing inflammatory molecules that damage surrounding tissue.15PubMed Central. Leukocyte-Rich Platelet-Rich Plasma as an Effective Source of Molecules That Modulate Local Immune and Inflammatory and Cell Responses In the context of cancer, immune modulation is a double-edged factor. Activating local immune cells might help surveil for residual cancer cells, or it might create inflammation that tumor cells exploit. Nobody has tested this in a controlled clinical trial specific to oncology patients.
This variability is a persistent problem for the entire PRP field, not just the cancer question. When one lab finds that PRP stimulates breast cancer cells and another finds it inhibits them, and both used “PRP,” they may have used products with very different growth factor profiles. Until preparation methods are standardized and studies specify exactly what formulation they tested, comparing results across studies remains frustrating.
Cosmetic PRP and the Cancer Survivor
The practical question many people are actually asking when they search this topic is whether they can safely get a PRP facial, PRP hair restoration, or a PRP-enhanced cosmetic procedure if they have a cancer history. The expert consensus described above gives a relatively clear framework: if your cancer was localized and you are now considered cured or in remission, PRP injections at a site far from where the cancer was are not contraindicated. If your cancer was metastatic, get your oncologist’s sign-off first.
What no guideline fully addresses is the gray zone of patients who are in remission but within the first few years, when recurrence risk is highest. A person two years out from early-stage breast cancer is in a very different risk category from someone ten years out, even though both might be described as “in remission.” The clinical studies showing safety at 30 months and roughly six years are helpful here, but they were conducted in surgical wound-healing contexts, not cosmetic ones. A PRP facial or scalp treatment involves injecting growth factors into an area with no known residual disease, which is conceptually lower risk than applying PRP to a fresh surgical wound near a tumor bed. But the honest answer is that the specific scenario of cosmetic PRP in recent cancer survivors has not been studied with the rigor that would let anyone make definitive safety claims.
What Researchers Still Need to Figure Out
The biggest gap in the evidence is a properly designed, large-scale clinical trial that tracks PRP use in cancer patients over many years. The studies that exist are either small, short in follow-up, or observational rather than randomized. Lab studies showing stimulation or inhibition of cancer cells are useful for generating hypotheses, but they cannot tell you what happens inside a person with a functioning immune system, blood supply, and complex tumor microenvironment.
Another unresolved question is dose-response. PRP concentrations vary enormously across commercial systems, with platelet counts anywhere from two to eight times baseline levels depending on the preparation kit. Whether a lower-concentration PRP carries less theoretical risk than a high-concentration one has not been studied in an oncology context. The same goes for injection volume and frequency: a single PRP treatment for a knee injury involves very different total growth factor exposure than a series of monthly PRP scalp treatments over a year.
There is also growing interest in whether modified forms of PRP, stripped of specific pro-angiogenic factors or enriched in anti-tumor immune cells, could be developed specifically for use in cancer patients who need wound healing support. That work is early-stage and mostly conceptual for now, but it reflects the recognition that the current one-size-fits-all approach to PRP formulation is a problem when the patient population includes people with cancer histories.